Is alendronate (Fosamax) safe to prescribe to a patient with a solitary kidney?

Can You Give Fosamax to a Patient with One Kidney?

Alendronate (Fosamax) can be prescribed to a patient with a solitary kidney, provided their creatinine clearance is ≥35 mL/min. The critical factor is renal function, not the number of kidneys.

Key Decision Point: Creatinine Clearance

The FDA label and clinical guidelines establish clear thresholds based on kidney function 1:

• CrCl ≥35 mL/min: Alendronate can be used with no dose adjustment required
• CrCl <35 mL/min: Alendronate is not recommended due to lack of experience in renal failure

Calculate creatinine clearance using the Cockcroft-Gault formula with actual body weight before prescribing 2. This is the standard used in drug approval studies and may differ from estimated GFR in some patients.

Clinical Reasoning

Having one kidney does not automatically contraindicate bisphosphonates. What matters is the functional capacity of the remaining kidney. Many patients with solitary kidneys maintain normal or near-normal renal function and can safely receive alendronate 2.

The 2020 AACE/ACE guidelines explicitly state that bisphosphonates should be used with caution "if at all" when GFR <35 mL/min for alendronate (or <30 mL/min for risedronate and ibandronate) 2. This caution stems from:

• Alendronate is primarily renally excreted (approximately 50% within 72 hours) 1
• Reduced renal clearance leads to greater drug accumulation in bone 1
• Theoretical nephrotoxicity concerns, though clinical evidence is limited 3

Evidence on Safety in Reduced Renal Function

Recent research provides reassuring data for patients with moderate renal impairment:

• A 2021 retrospective study found that alendronate use in patients with CrCl <35 mL/min showed no significant deterioration in renal function compared to untreated controls over 22 months 4
• A 2020 study demonstrated that alendronate improved bone mineral density by 2-3% per year in women with CKD stages 3B-5 5
• Multiple studies show alendronate is well-tolerated in patients with renal impairment when used appropriately 6, 7

However, these are observational studies with limitations, and the FDA label remains the authoritative source for prescribing decisions.

Alternative Considerations

If your patient's CrCl is <35 mL/min, denosumab is the preferred alternative 2:

• Denosumab is not contraindicated in renal insufficiency
• No dose adjustment required regardless of kidney function
• Important caveat: Higher risk of hypocalcemia in severe renal impairment—monitor calcium closely and ensure adequate supplementation 2
• Recent evidence shows comparable efficacy to alendronate in kidney transplant patients 8

The 2025 KDIGO guidelines note that while bone-targeting agents have safety concerns in CKD, bisphosphonates can be considered in kidney transplant patients based on BMD and clinical risk factors 3.

Common Pitfalls to Avoid

1. Don't assume one kidney = contraindication: Always calculate actual creatinine clearance
2. Don't use eGFR alone: The Cockcroft-Gault formula is specifically required for bisphosphonate dosing decisions 2
3. Don't forget to correct hypocalcemia first: This is an absolute contraindication regardless of renal function 2, 1
4. Monitor for acute kidney injury: While rare, there's a theoretical increased risk with bisphosphonates in compromised renal function 4

Practical Algorithm

1. Calculate creatinine clearance using Cockcroft-Gault formula
2. Check serum calcium (correct hypocalcemia before starting)
3. If CrCl ≥35 mL/min: Prescribe alendronate 70 mg weekly
4. If CrCl <35 mL/min: Consider denosumab 60 mg subcutaneously every 6 months instead
5. Ensure adequate calcium (1000-1200 mg daily) and vitamin D supplementation in all cases
6. Monitor renal function periodically during treatment

Bottom line: A solitary kidney is not a contraindication to Fosamax—adequate renal function (CrCl ≥35 mL/min) is what determines safety 1.